In summary, PD-1/PD-L1 inhibitors as first-line monotherapy can be considered the standard of care in patients with advanced NSCLC and PD-L1 expression ≥50% without targetable mutations. This evidence concerns the gene CD274 and non-small cell lung carcinoma.